Cenicriviroc Improves Fibrosis in Patients With Fatty Liver Cenicriviroc Improves Fibrosis in Patients With Fatty Liver

The investigational drug is designed to interrupt the inflammatory cascade that leads to fibrosis and cirrhosis in patients with severe nonalcoholic steatohepatitis (NASH).Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news